Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.

Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M.

Biol Blood Marrow Transplant. 2018 Dec 18. pii: S1083-8791(18)30891-7. doi: 10.1016/j.bbmt.2018.12.069. [Epub ahead of print]

PMID:
30572109
2.

Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.

Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL.

Biol Blood Marrow Transplant. 2018 Nov 10. pii: S1083-8791(18)30698-0. doi: 10.1016/j.bbmt.2018.11.004. [Epub ahead of print]

PMID:
30423480
3.

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors.

Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE.

Haematologica. 2018 Oct 31. pii: haematol.2018.200121. doi: 10.3324/haematol.2018.200121. [Epub ahead of print]

4.

Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome.

Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1664-1670. doi: 10.1016/j.bbmt.2018.04.010. Epub 2018 Apr 19.

PMID:
29680516
5.

Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation.

Epperla N, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, Craig MD, Kanate AS, Bachanova V.

Biol Blood Marrow Transplant. 2018 May;24(5):983-988. doi: 10.1016/j.bbmt.2018.01.015. Epub 2018 Feb 2.

PMID:
29410340
6.

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.

Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN.

JAMA Oncol. 2018 Mar 1;4(3):343-350. doi: 10.1001/jamaoncol.2017.4600.

7.

Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.

Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S.

Br J Haematol. 2017 Dec;179(5):781-789. doi: 10.1111/bjh.14954. Epub 2017 Oct 4.

PMID:
28980314
8.

Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients.

Gajewski JL, McClellan MB, Majhail NS, Hari PN, Bredeson CN, Maziarz RT, LeMaistre CF, Lill MC, Farnia SH, Komanduri KV, Boo MJ.

Biol Blood Marrow Transplant. 2018 Jan;24(1):4-12. doi: 10.1016/j.bbmt.2017.09.012. Epub 2017 Sep 28.

9.

Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation.

Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske TS.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):408-414. doi: 10.1016/j.clml.2017.05.005. Epub 2017 May 12.

PMID:
28756899
10.

Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease.

Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN.

Am J Hematol. 2017 Oct;92(10):E610-E611. doi: 10.1002/ajh.24850. Epub 2017 Jul 29. No abstract available.

11.

Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.

Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A.

Cancer. 2017 Aug 15;123(16):3141-3149. doi: 10.1002/cncr.30747. Epub 2017 May 4.

12.

Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.

Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1295-1302. doi: 10.1016/j.bbmt.2017.04.009. Epub 2017 Apr 12.

13.

Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.

Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS.

Hematol Oncol. 2017 Dec;35(4):528-535. doi: 10.1002/hon.2380. Epub 2017 Jan 8.

PMID:
28066928
14.

Instrumental variable with competing risk model.

Zheng C, Dai R, Hari PN, Zhang MJ.

Stat Med. 2017 Apr 15;36(8):1240-1255. doi: 10.1002/sim.7205. Epub 2017 Jan 8.

15.

Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation.

Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS.

Clin Lymphoma Myeloma Leuk. 2016 Dec;16(12):672-678. doi: 10.1016/j.clml.2016.08.018. Epub 2016 Aug 29.

PMID:
27660080
16.

Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft.

Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M.

Bone Marrow Transplant. 2017 Jan;52(1):147-150. doi: 10.1038/bmt.2016.200. Epub 2016 Aug 1. No abstract available.

PMID:
27479688
17.

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.

Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M.

J Clin Oncol. 2016 Sep 10;34(26):3141-9. doi: 10.1200/JCO.2015.66.3476. Epub 2016 Jun 6.

18.

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.

Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN.

Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):379-86. doi: 10.1016/j.clml.2016.03.001. Epub 2016 Mar 30.

PMID:
27160644
19.

Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity.

Costa LJ, Hari PN, Kumar SK.

Leuk Lymphoma. 2016 Dec;57(12):2827-2832. Epub 2016 Apr 22.

PMID:
27104965
20.

Allogeneic stem cell transplantation for multiple myeloma: is there a future?

Dhakal B, Vesole DH, Hari PN.

Bone Marrow Transplant. 2016 Apr;51(4):492-500. doi: 10.1038/bmt.2015.325. Epub 2016 Jan 4. Review.

PMID:
26726943
21.

Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms.

Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC.

Bone Marrow Transplant. 2016 Apr;51(4):617-8. doi: 10.1038/bmt.2015.295. Epub 2016 Jan 4. No abstract available.

PMID:
26726940
22.

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.

Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M.

Bone Marrow Transplant. 2016 Jan;51(1):58-66. doi: 10.1038/bmt.2015.223. Epub 2015 Oct 5.

23.

Ibrutinib in Refractory Classic Hodgkin's Lymphoma.

Hamadani M, Balasubramanian S, Hari PN.

N Engl J Med. 2015 Oct;373(14):1381-2. doi: 10.1056/NEJMc1505857. No abstract available.

PMID:
26422743
24.

Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas.

Epperla N, Fenske TS, Hari PN, Hamadani M.

World J Transplant. 2015 Sep 24;5(3):81-8. doi: 10.5500/wjt.v5.i3.81. Review.

25.

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.

Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A.

Bone Marrow Transplant. 2015 Dec;50(12):1513-8. doi: 10.1038/bmt.2015.190. Epub 2015 Aug 24.

26.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2091-2099. doi: 10.1016/j.bbmt.2015.07.028. Epub 2015 Aug 4.

27.

Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.

Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN.

Bone Marrow Transplant. 2015 Jul;50(7):914-7. doi: 10.1038/bmt.2015.73. Epub 2015 Apr 27.

PMID:
25915809
28.

Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis.

Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M.

Bone Marrow Transplant. 2015 Apr;50(4):610-2. doi: 10.1038/bmt.2014.318. Epub 2015 Jan 26. No abstract available.

PMID:
25621807
29.

New cancers after autotransplantations for multiple myeloma.

Mahindra A, Raval G, Mehta P, Brazauskas R, Zhang MJ, Zhong X, Bird JM, Freytes CO, Hale GA, Herzig R, Holmberg LA, Kamble RT, Kumar S, Lazarus HM, Majhail NS, Marks DI, Moreb JS, Olsson R, Saber W, Savani BN, Schiller GJ, Tay J, Vogl DT, Waller EK, Wiernik PH, Wirk B, Lonial S, Krishnan AY, Dispenzieri A, Brandenburg NA, Gale RP, Hari PN.

Biol Blood Marrow Transplant. 2015 Apr;21(4):738-45. doi: 10.1016/j.bbmt.2014.12.028. Epub 2014 Dec 31.

30.

Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma.

Costa LJ, Huang JX, Hari PN.

Biol Blood Marrow Transplant. 2015 Apr;21(4):701-6. doi: 10.1016/j.bbmt.2014.12.024. Epub 2014 Dec 30.

31.

Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.

Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN.

Biol Blood Marrow Transplant. 2015 Feb;21(2):335-41. doi: 10.1016/j.bbmt.2014.10.023. Epub 2014 Nov 1.

32.

Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes.

Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, Hamadani M, Hari PN.

Bone Marrow Transplant. 2015 Mar;50(3):449-51. doi: 10.1038/bmt.2014.261. Epub 2014 Nov 10. No abstract available.

PMID:
25387097
33.

Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis.

Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M.

Biol Blood Marrow Transplant. 2014 Dec;20(12):1926-31. doi: 10.1016/j.bbmt.2014.08.002. Epub 2014 Aug 8.

34.

Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome.

Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, Hale GA, Maharaj D, Gale RP, Rowlings PA, Freytes CO, Miller AM, Vose JM, Maziarz RT, Montoto S, Maloney DG, Hari PN.

Bone Marrow Transplant. 2014 Nov;49(11):1360-5. doi: 10.1038/bmt.2014.161. Epub 2014 Jul 28.

35.

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.

Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36. doi: 10.1016/j.bbmt.2014.06.036. Epub 2014 Jul 5.

36.

Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age.

Michaelis LC, Hamadani M, Hari PN.

Expert Rev Hematol. 2014 Jun;7(3):321-4. doi: 10.1586/17474086.2014.913978. Epub 2014 May 2.

PMID:
24785114
37.

Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions.

Kanate AS, Pasquini MC, Hari PN, Hamadani M.

World J Stem Cells. 2014 Apr 26;6(2):69-81. doi: 10.4252/wjsc.v6.i2.69. Review.

38.

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.

Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN.

J Clin Oncol. 2014 Feb 1;32(4):273-81. doi: 10.1200/JCO.2013.49.2454. Epub 2013 Dec 16.

39.

Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.

Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN.

Biol Blood Marrow Transplant. 2014 Mar;20(3):402-408.e1. doi: 10.1016/j.bbmt.2013.12.557. Epub 2013 Dec 14.

40.

Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation.

Freytes CO, Vesole DH, LeRademacher J, Zhong X, Gale RP, Kyle RA, Reece DE, Gibson J, Schouten HC, McCarthy PL, Lonial S, Krishnan AY, Dispenzieri A, Hari PN.

Bone Marrow Transplant. 2014 Mar;49(3):416-21. doi: 10.1038/bmt.2013.187. Epub 2013 Nov 25.

41.

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.

Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W.

Biol Blood Marrow Transplant. 2014 Jan;20(1):89-97. doi: 10.1016/j.bbmt.2013.10.018. Epub 2013 Oct 23.

42.

Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.

Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG, Montoto S, Hari PN.

Biol Blood Marrow Transplant. 2013 Dec;19(12):1740-4. doi: 10.1016/j.bbmt.2013.09.018. Epub 2013 Oct 3.

43.

Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.

Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, Freytes C, Vesole D, Gale RP, Anderson K, Wirk B, Savani BN, Waller EK, Schouten H, Lazarus H, Meehan K, Sharma M, Kamble R, Vij R, Kumar S, Nishihori T, Kindwall-Keller T, Saber W, Hari PN.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1615-24. doi: 10.1016/j.bbmt.2013.08.002. Epub 2013 Aug 11.

44.

Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.

Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN.

J Clin Oncol. 2013 Sep 1;31(25):3100-9. doi: 10.1200/JCO.2012.46.0188. Epub 2013 Jul 29.

45.

Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.

Maziarz RT, Wang Z, Zhang MJ, Bolwell BJ, Chen AI, Fenske TS, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM, Holmberg L, Inwards DJ, Isola LM, Khoury HJ, Lewis VA, Maharaj D, Munker R, Phillips GL, Rizzieri DA, Rowlings PA, Saber W, Satwani P, Waller EK, Maloney DG, Montoto S, Laport GG, Vose JM, Lazarus HM, Hari PN.

Br J Haematol. 2013 Sep;162(5):648-56. doi: 10.1111/bjh.12451. Epub 2013 Jul 6.

46.

Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.

Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM.

Biol Blood Marrow Transplant. 2013 May;19(5):746-53. doi: 10.1016/j.bbmt.2013.01.024. Epub 2013 Feb 1.

47.

Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.

Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM.

Biol Blood Marrow Transplant. 2013 Apr;19(4):625-31. doi: 10.1016/j.bbmt.2013.01.009. Epub 2013 Jan 17.

48.

Multiple myeloma: future directions in autologous transplantation and novel agents.

Hari PN, McCarthy PL.

Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S20-5. doi: 10.1016/j.bbmt.2012.11.002. Review. No abstract available.

49.

Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.

Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL.

Biol Blood Marrow Transplant. 2013 Feb;19(2):173-9. doi: 10.1016/j.bbmt.2012.11.016. Epub 2012 Nov 27.

50.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, Fenske TS, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN; Lymphoma Working Committee of the CIBMTR.

Blood. 2012 Nov 15;120(20):4256-62. doi: 10.1182/blood-2012-06-436725. Epub 2012 Sep 24.

Supplemental Content

Support Center